MedTrace Logo

PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

NCT00459836 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2011-03-02

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as PR-104, docetaxel, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of PR-104 when given together with docetaxel or gemcitabine in treating patients with solid tumors.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

PR-104

DRUG

docetaxel

DRUG

gemcitabine hydrochloride

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Sponsors & Collaborators

  • Proacta, Incorporated

    lead INDUSTRY

Principal Investigators

  • Terri J. Melink, NP, MSN, ANP · Proacta, Incorporated

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-10-31

Countries

  • United States
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00459836 on ClinicalTrials.gov